Analysts expect Dyne Therapeutics, Inc. to report revenue of 0.00 for Q3 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 26, came in at 0.00.
| Metric | Q1 15 | Q2 15 | Q3 15 | Q4 15 | Q1 16 | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 632.00 M | 990.00 M | 1.23 B | 1.02 B | 1.12 B | 904.00 M | 1.18 B | 1.11 B | 1.25 B | 1.16 B | 1.44 B | 994.00 M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 743.62 M | 1.13 B | 1.24 B | 1.26 B | 993.61 M | 895.03 M | 1.37 B | 1.02 B | 1.39 B | 943.78 M | 1.49 B | 1.29 B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.35 M | 7.61 M | 68.46 M | 22.46 M | 30.54 M | 56.18 M | ||||||||||
| Low Estimate | 658.70 M | 1.05 B | 1.06 B | 1.15 B | 929.91 M | 811.93 M | 1.18 B | 915.67 M | 1.26 B | 884.14 M | 1.37 B | 1.18 B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.87 M | 6.99 M | 63.40 M | 20.75 M | 25.63 M | 49.94 M | ||||||||||
| Consensus Estimate | 701.16 M | 1.09 B | 1.15 B | 1.21 B | 961.76 M | 853.48 M | 1.28 B | 967.75 M | 1.32 B | 913.96 M | 1.43 B | 1.24 B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.11 M | 7.30 M | 65.93 M | 21.60 M | 28.08 M | 53.06 M |
Analysts expect Dyne Therapeutics, Inc. to report earnings per share of -0.94 for Q3 26, against a range of -0.99 to -0.89. The most recent reported quarter, Q2 26, came in at -1.08, a 36.7% miss against the -0.79 consensus.
| Metric | Q1 15 | Q2 15 | Q3 15 | Q4 15 | Q1 16 | Q2 16 | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.93 | 2.73 | 0.40 | -1.09 | -0.13 | -1.22 | 0.04 | -0.72 | -0.98 | -1.13 | 0.23 | -0.66 | -0.96 | -0.88 | -1.05 | -0.97 | -0.76 | -0.76 | -0.73 | -1.08 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -0.46 | -0.26 | 0.20 | -0.98 | -0.70 | -0.94 | 0.37 | 0.92 | -0.44 | -0.19 | 0.66 | -0.30 | -0.61 | -0.94 | -0.75 | -0.84 | -0.84 | -0.74 | -0.76 | -0.75 | -0.89 | -0.86 | -0.77 | -0.75 | -0.58 | -0.66 | -0.82 | -0.73 | ||||||||||
| Low Estimate | -0.52 | -0.28 | 0.18 | -1.14 | -0.82 | -1.02 | 0.33 | 0.80 | -0.50 | -0.23 | 0.62 | -0.34 | -0.71 | -1.02 | -0.89 | -0.94 | -0.92 | -0.86 | -0.82 | -0.83 | -0.99 | -1.00 | -0.89 | -0.91 | -0.68 | -0.74 | -0.94 | -0.81 | ||||||||||
| Consensus Estimate | -0.49 | -0.27 | 0.19 | -1.06 | -0.76 | -0.98 | 0.35 | 0.86 | -0.47 | -0.21 | 0.64 | -0.32 | -0.66 | -0.98 | -0.82 | -0.89 | -0.88 | -0.80 | -0.79 | -0.79 | -0.94 | -0.93 | -0.83 | -0.83 | -0.63 | -0.70 | -0.88 | -0.77 |
Pull Wall Street consensus for Dyne Therapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=DYN&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "DYN", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=DYN&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();